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OBJECTIVES: To evaluate the cost-effectiveness of three tobacco
cessation pharmacotherapy strategies: varenicline only, nicotine
transdermal patch plus nicotine polacrilex gum (NRT), and
bupropion plus nicotine transdermal patch. All patients also
received multiple individual sessions of cognitive behavioral and
motivational intervention, as part of the Tobacco Treatment
Program (TTP) for cancer patients at M.D. Anderson Cancer
Center. Patients with psychiatric disorders were assessed and
treated by the program psychiatrist. METHODS: A decision
analytical model was developed and populated with retrospective
cost and outcomes data from the TTP databases. The model
estimated the incremental cost-effectiveness of the three afore-
mentioned strategies for the treatment of tobacco addiction.
Costs included direct institutional medication costs, and the
direct costs plus institutional overhead for counseling and psy-
chiatric sessions. All costs were adjusted to January 2008 dollars.
The model was evaluated for two outcomes of interest: 1)
tobacco cessation—deﬁned as seven-day abstinence after 12
weeks of therapy, and 2) tobacco use reduction of at least 50%
after 12 weeks. RESULTS: Efﬁcacy and utilization data from 281
patients in the TTP were used to populate the model. The results
showed that NRT (patch plus gum) was the least costly strategy
for quitting. However, varenicline was more effective, with an
incremental cost-effectiveness of $3,778 per quit event. For
reducing tobacco use by at least 50%, NRT was most cost-
effective, being the least costly and most effective; dominating the
other two strategies for that outcome. CONCLUSIONS: In this
sample of cancer patients, NRT in the form of the nicotine
transdermal patch and gum appears to be a cost-effective option
for reducing tobacco use, although varenicline was found to be
most effective when only considering quit rates. The results
of this study provide preliminary evidence to guide decision
making regarding pharmacotherapy options in tobacco cessation
programs.
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OBJECTIVES: Trastuzumab (Herceptin®) combined with stan-
dard chemotherapy has demonstrated a signiﬁcant improvement
in time to progression and overall survival in early breast cancer
(EBC) patients over-expressing human epidermal growth factor
receptor (HER-2). The objective of this study is to estimate the
long-term clinical and economic outcomes of one year of adju-
vant Herceptin® therapy in Spanish HER2-positive EBC patients.
METHODS: An analytic Markov model was based on the results
from the pivotal international clinical study (HERA). The model
simulated long-term clinical outcomes and costs of adding Her-
ceptin® during one year sequentially to standard adjuvant che-
motherapy versus standard alone in EBC patients. The health
states included loco-regional and distant recurrences (metasta-
sis), cardiac events (side-effects), disease free survival and death.
Improvements in lifetime QALY were also estimated. Model
transition probabilities were based on HERA results. Yearly costs
in each health state show medical practice in Spanish hospitals
and came from questionnaires ﬁlled in by oncologists, published
sources and local databases. Medical records of 31 metastatic
breast cancer patients were reviewed to estimate the annual cost
of this health state. Direct costs and health outcomes were pro-
jected over a 10-year horizon from the Spanish National Health
System (SNHS) perspective. Both variables were discounted at an
annual rate of 3.5%. A sensitivity analysis was performed.
RESULTS: For a cohort of 1000 patients with a 10-year follow-
up, adjuvant therapy with Herceptin® would prevent 195.0
loco-regional recurrences, 755.8 distant recurrences and 114.7
deaths. ICER estimated for Herceptin® was €16,834 in a 10-year
horizon. This estimate is well below the non-explicit but com-
monly accepted efﬁciency threshold in Spain (€30,000). CON-
CLUSIONS: Adding up the monoclonal antibody Herceptin®
(Trastuzumab) to standard chemotherapy for the treatment of
patients with primary HER-2 positive EBC signiﬁcantly improves
overall survival. Such an improvement can be attained in the
SNHS with a relatively acceptable ICER.
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OBJECTIVES: To model the cost-effectiveness of sunitinib versus
sorafenib, temsirolimus and bevacizumab + interferon (IFN) as
ﬁrst-line therapy for mRCC in the Swedish health service setting.
METHODS: An adapted Markov model was created using data
collected from clinical trials. Patient-level data and parametric
survival curves obtained from a comparative trial of sunitinib
versus IFN were extrapolated to 10 years. Indirect comparison of
the efﬁcacy of sorafenib, temsirolimus and bevacizumab + IFN
versus the IFN arm of clinical trials generated progression-free
survival (PFS) and overall survival (OS) data. First-line therapy
determined the choice of second-line therapy and the proportion
of patients receiving best supportive care after progression.
Resources speciﬁc to Sweden included drugs, tests, scans, moni-
toring, physician visits, hospitalisations and AE management.
Outcome measures included life-years (LY), progression-free LY
(PFLY), and quality-adjusted LY (QALY) gained. RESULTS:
Sunitinib had the greatest projected PFS and OS. Incremental
10-year cost-effectiveness ratios for sunitinib versus sorafenib
were Swedish krona (SEK) 120,300/PFLY, SEK177,900/LY and
SEK210,200/QALY gained. Sunitinib dominated temsirolimus
and bevacizumab + IFN, since both were more costly and less
effective. At a threshold for societal willingness to pay of
SEK500,000/QALY gained, sunitinib has the highest probability
of being the most cost-effective therapy. In this model, key drivers
were hazard ratios for PFS and OS, drug costs and the percentage
of patients with second-line therapy. The update on PFS and OS
for sunitinib and IFN presented at the ASCO 2008 meeting is in
line with predicted values in the model and hence conﬁrms the
robustness of the results. CONCLUSIONS: In the Swedish health
service setting, sunitinib is a cost-effective option for ﬁrst-line
mRCC therapy compared with sorafenib, temsirolimus and
bevacizumab + IFN. Sunitinib had the highest probability of
being the most cost-effective treatment at a SEK500,000/QALY
threshold for societal willingness to pay for clinical beneﬁt.
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